WallStreetZenWallStreetZen

NASDAQ: DMAC
Diamedica Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

DMAC past revenue growth

How has DMAC's revenue growth performed historically?
Company
N/A
Industry
69.59%
Market
14.15%
DMAC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
DMAC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

DMAC earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$15.4M
Current Profit Margin
0%

DMAC Return on Equity

Current Company
-46.7%
Current Industry
-18%
Current Market
30.8%
DMAC's Return on Equity (-46.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when DMAC announces earnings.

DMAC Return on Assets

Current Company
-43.6%
Current Industry
0.9%
DMAC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

DMAC Return on Capital Employed

Current Company
-55.96%
Current Industry
14.1%
DMAC has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

DMAC vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
DMAC$0.00-$15.24M-$15.36M-100.00%N/A
LGVN$1.13M-$19.03M-$19.97M-48.70%N/A
PIRS$16.85M-$38.85M-$41.36M-9.71%N/A
CRDF$395.00k-$38.64M-$38.96M-5.00%N/A
CSBR$53.68M-$841.00k-$3.12M+23.04%N/A
View Top Biotech Stocks

Diamedica Therapeutics Earnings & Revenue FAQ

What were DMAC's earnings last quarter?

On Invalid Date, Diamedica Therapeutics (NASDAQ: DMAC) reported Q1 2023 earnings per share (EPS) of -$0.20, up 53.85% year over year. Total Diamedica Therapeutics earnings for the quarter were -$5.23 million. In the same quarter last year, Diamedica Therapeutics's earnings per share (EPS) was -$0.13.

If you're new to stock investing, here's how to buy Diamedica Therapeutics stock.

What was DMAC's earnings growth in the past year?

As of Q2 2023, Diamedica Therapeutics's earnings has grown year over year. Diamedica Therapeutics's earnings in the past year totalled -$15.36 million.

What was DMAC's revenue last quarter?

On Invalid Date, Diamedica Therapeutics (NASDAQ: DMAC) reported Q1 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Diamedica Therapeutics's revenue was $0.00.

What was DMAC's revenue growth in the past year?

As of Q2 2023, Diamedica Therapeutics's revenue has grown null year over year. Diamedica Therapeutics's revenue in the past year totalled $0.00.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.